- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Palliative Care and Healthcare Utilization
Genevieve Kumapley, PharmD, BCOP, discusses the importance of introducing palliative care to patients at the time of diagnosis. Specifically, she describes how a multidisciplinary team approach can affect the utilization of healthcare resources. If such an approach is taken early, there is significant potential for cost savings, she suggests.
Addressing palliative care early on, and in a multidisciplinary manner, helps all stakeholders understand the goals and preferences of the patient. As part of the team approach, members of a patient’s palliative care team discuss with the patient what tests and/or treatments will or will not be beneficial, says Dr Kumapley. By having these discussions and taking into account the patient’s preferences, the patient’s palliative care team can potentially decrease the overuse of healthcare resources, which may result in cost savings.
As a pharmacist, Dr Kumapley discusses the pharmacist’s role in palliative care. Pharmacists have the opportunity to improve patient adherence by helping patients recognize adverse events and understand how to properly manage them, she says.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
